BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Therapeutic Court Association of Washington and Washington Association of Drug Courts - ECPv6.16.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://tcaofwa.org
X-WR-CALDESC:Events for Therapeutic Court Association of Washington and Washington Association of Drug Courts
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260423T000000
DTEND;TZID=America/Los_Angeles:20260424T235959
DTSTAMP:20260311T050957Z
CREATED:20260311T050957Z
LAST-MODIFIED:20260311T050957Z
UID:9007-1776902400-1777075199@tcaofwa.org
SUMMARY:TeleBehavioral Health Summit: Artificial Intelligence in Behavioral Health
DESCRIPTION:Brought to you by HCA/University of Washington \nThe Behavioral Health Institute is pleased to offer the 2026 TeleBehavioral Health Summit\, generously funded by the Washington State Legislature\, in partnership with the Northwest Regional Telehealth Resource Center (NRTRC). \nThis two-day summit brings together national experts\, clinicians\, policymakers\, and behavioral health leaders to explore the practical\, ethical\, and regulatory dimensions of AI in mental health and substance use care. \nDesigned for clinicians\, peer professionals\, administrators\, and system leaders\, the Summit focuses on real-world applications of AI — supporting safe\, effective\, and responsible integration into behavioral health practice. \nJoin us for timely\, frontline-focused education on what’s here now\, what’s emerging\, and how to stay grounded in an evolving digital care landscape. \nCredit Offered: AMA PRA Category 1 Credit™; Nursing contact hours; Interprofessional Continuing Education (IPCE). Full accreditation information can be found at the BHI Continuing Education & Accreditation webpage. \nDates and times\n\nThursday\, April 23: 9:30 a.m. – 3:30 p.m.\nFriday\, April 24: 10 a.m. – 3:45 p.m.\n\nRegister Here: \nAirmeet: 2026 TeleBehavioral Health Summit
URL:https://tcaofwa.org/event/telebehavioral-health-summit-artificial-intelligence-in-behavioral-health/
LOCATION:Online
CATEGORIES:Conference,Treatment
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-10-220852.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260413T110000
DTEND;TZID=America/Los_Angeles:20260413T120000
DTSTAMP:20260327T005846Z
CREATED:20260327T005846Z
LAST-MODIFIED:20260327T005846Z
UID:9270-1776078000-1776081600@tcaofwa.org
SUMMARY:Medetomidine Impacts on Clinical Management and Systems of Care
DESCRIPTION:ORN Partner Organization Sponsor: American Osteopathic Academy of Addiction Medicine (AOAAM) \nWednesday May 13\, 2026 5:00 – 6:00 PM ET \nMedetomidine\, a highly potent veterinary alpha-2 adrenergic agonist\, has recently emerged as a significant adulterant within the U.S. illicit opioid supply. This presentation will review the introduction of medetomidine in the U.S. drug supply\, the pharmacology and clinical effects of medetomidine\, and the distinguishing features of medetomidine toxicity and withdrawal. We will outline emerging treatment strategies emphasizing early\, aggressive alpha-2 agonist therapy; nuanced antiemetic approaches; when and how to escalate to IV dexmedetomidine; and approaches to concurrent opioid withdrawal management. Participants will gain insight into diagnostic challenges\, observation and disposition considerations\, and strategies for system-level preparedness. \nDescription:\n\nMedetomidine\, a highly potent veterinary alpha-2 adrenergic agonist\, has recently emerged as a significant adulterant within the U.S. illicit opioid supply. This presentation entitled will review the introduction of medetomidine in the U.S. drug supply\, the pharmacology and clinical effects of medetomidine\, and the distinguishing features of medetomidine toxicity and withdrawal. We will outline emerging treatment strategies emphasizing early\, aggressive alpha-2 agonist therapy; nuanced antiemetic approaches; when and how to escalate to IV dexmedetomidine; and approaches to concurrent opioid withdrawal management. Participants will gain insight into diagnostic challenges\, observation and disposition considerations\, and strategies for system-level preparedness. \nLearning objectives:\nAt the conclusion of this seminar\, attendees should be able to: \n\nDescribe the emergence of medetomidine as an illicit drug adulterant and its impact on overdose toxicity and withdrawal presentations.\nRecognize the clinical features of medetomidine toxicity and differentiate medetomidine withdrawal from withdrawal syndromes.\nApply evidence-informed strategies for early\, aggressive management of medetomidine withdrawal\, including the use of alpha-2 agonists and antiemetic therapies.\nIdentify system-level challenges posed by medetomidine and outline approaches to multidisciplinary coordination.\n\nWhat is ORN\n\n\nHelp is here! The Opioid Response Network (ORN) is your resource for no-cost education\, training and consultation to enhance efforts addressing opioid and stimulant use disorders.\nORN has consultants in every state and territory to deploy across prevention\, treatment\, recovery and harm reduction.\nShare your needs via the “Submit a Request” form at www.OpioidResponseNetwork.org. Within one business day\, your regional point person will be in touch to learn more.\n\nSpeaker: \nMichael Lynch\, MD \n\nDr. Michael Lynch is an associate professor of Emergency Medicine\, Toxicology\, and Addiction Medicine at the University of Pittsburgh where he works clinically in several UPMC hospitals. He is currently Senior Medical Director for Quality and Substance Use Disorder Services at UPMC Health Plan. He previously served as the first Medical Director of the PA Department of Drug and Alcohol Programs and was Medical Director of the Pittsburgh Poison Center for 10 years. Dr. Lynch is the founder and director of the UPMC Medical Toxicology Telemedicine Bridge Clinic. \nDISCLAIMER\nACCREDITATION:\nIn support of improving patient care\, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. \nDISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:\nAll conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships\, or the lack thereof\, will be provided to learners.\n\nFunding:\nFunding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names\, commercial practices\, or organizations imply endorsement by the U.S. Government.\n\n\n\nRegister Here: ORN Spring 2026: Medetomidine Impacts on Clinical Management and Systems of Care\n\n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/medetomidine-impacts-on-clinical-management-and-systems-of-care/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Treatment,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-26-175327.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260403T090000
DTEND;TZID=America/Los_Angeles:20260403T100000
DTSTAMP:20260327T004538Z
CREATED:20260327T004538Z
LAST-MODIFIED:20260327T004538Z
UID:9260-1775206800-1775210400@tcaofwa.org
SUMMARY:Evidence-Based Treatment for Stimulant Use Disorders Among Populations at Elevated Risk for HIV
DESCRIPTION:Brought to you by Opioid Research Network \nEvidence-Based Treatment for Stimulant Use Disorders Among Populations at Elevated Risk for HIV \nFriday April 3\, 2026 12:00 – 1:00 PM ET \nORN Partner Organization Sponsor: National Alliance for HIV Education and Workforce Development (NAHEWD) \nThis lecture will review safety optimization strategies and evidence-based treatments for stimulant use disorders\, including special attention to populations at elevated risk of HIV. The session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series is highlighting various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. \nThis session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series will highlight various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. This lecture will review safety optimization strategies and evidence-based treatments for stimulant use disorders\, including special attention to populations at elevated risk of HIV. By the end of the presentation\, participants will be able to: 1. Contextualize stimulant use disorder and substance use among populations at elevated risk for HIV using epidemiology and syndemic theory. 2. Apply safety optimization techniques to support the wellness of people who use stimulants. 3. Translate clinical research on treatments for stimulants into therapeutic prescribing practices. \nRegister Here: Webinar Registration – Zoom
URL:https://tcaofwa.org/event/evidence-based-treatment-for-stimulant-use-disorders-among-populations-at-elevated-risk-for-hiv/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Treatment,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-26-174430.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260402T080000
DTEND;TZID=America/Los_Angeles:20260402T170000
DTSTAMP:20260403T004148Z
CREATED:20260403T004148Z
LAST-MODIFIED:20260403T004148Z
UID:9523-1775116800-1775149200@tcaofwa.org
SUMMARY:Ask the Expert: Exploring Metabolic Psychiatry
DESCRIPTION:Brought to you by NAMI:  \nThursday\, April 9\, 2026 | 4:00 – 5:30 p.m. ET \nWant to learn more about the cutting-edge science of metabolic psychiatry?\nThis webinar will explore metabolic therapies for psychiatric conditions from both a clinical and lived experience perspective.\nDr. Calogero (Carlo) Longhitano\, psychiatrist and Associate Professor of Psychiatry at James Cook University (JCU)\, will share his insights on the potential of ketogenic therapy as both a clinician and researcher. He is co-investigator of JCU’s randomized controlled trial comparing a ketogenic diet with a standard diet in adults with bipolar disorder and schizophrenia.\nHannah Warren will share her experience of putting symptoms of bipolar I disorder into remission using metabolic therapies\, including a ketogenic diet. She will also discuss testimonials from additional individuals with a wide variety of diagnoses. \nYou’ll hear more about:\n•	The potential for meaningful improvements in both mental and physical health through ketogenic therapy\n•	How to mitigate risks and access the growing number of resources available to help individuals explore this promising intervention safely\n•	How a grassroots movement is emerging to expand awareness of an access to metabolic therapies for psychiatric conditions\nWhether you’re seeking answers for yourself\, a loved one\, or your patients\, this session will provide cutting-edge information grounded in the latest research and lived experience. \nReserve your spot today and submit your questions for our presenters through the registration form!  https://nami-org.zoom.us/webinar/register/WN_jGyO45I4TI2jN3-bOvRp6g#/registration \nGuest Prsenters:\nDr. Carlo Longhitano\, MD \nAssociate Professor of Psychiatry\nJames Cook University\, Australia \nCarlo Longhitano is the Associate Professor of Psychiatry at James Cook University medical school and a psychiatrist at North Queensland Forensic MH Services. He obtained his MD in 1999 (Italy) before completing his psychiatric residency in Oxford and London (UK) where he held senior positions before moving to Townsville\, Australia\, in 2018. Carlo is completing a PhD project on the effects of nutritional interventions in psychosis. He is the co-investigator with Prof Zoltan Sarnyai at JCU’s randomized clinical trial of ketogenic metabolic therapy vs standard diet in adults with bipolar disorder and schizophrenia. The project is supported and funded by the US-based Baszucki Brain Research Foundation. Additionally\, Carlo is a member of the forensic faculty of the RANZCP\, a board member at Margaret Roderick Centre for MH Research and a scientific advisor to the Australasian Metabolic Health Society. He is the author of several peer-reviewed articles and two textbook chapters.  \nHannah Warren \nLived Experience Advocate\, Communications & Advocacy Manager\nMetabolic Mind \nHannah serves as Communications and Advocacy Manager at Baszucki Group and Metabolic Mind\, where she works to advance awareness of metabolic psychiatry. Following her remission from bipolar I disorder through ketogenic therapy in 2021\, she dedicated herself to sharing the growing scientific foundation of metabolic therapies and promoting their potential as first-line interventions.\nShe is cofounder of Metabolic Collective\, a nonprofit organization building grassroots communities to expand awareness of and access to metabolic therapies for psychiatric and neurological conditions.\nHannah has spent much of her career in the nonprofit sector\, most recently serving as Marketing and Development Director at Serenity Hospice and Home.\nShe holds an M.A. in Fashion Entrepreneurship from the London College of Fashion and a B.A. in South Asian Studies and Linguistics from the School of Oriental and African Studies\, University of London. She is currently writing a book titled Radiant Beast: The Mitochondrial Pathway. \n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/ask-the-expert-exploring-metabolic-psychiatry/
LOCATION:Online
CATEGORIES:Advocacy,Behavioral Health,Office Hours,Treatment
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/04/Screenshot-2026-04-02-173824.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260319T130000
DTEND;TZID=America/Los_Angeles:20260319T143000
DTSTAMP:20260306T210112Z
CREATED:20260306T210112Z
LAST-MODIFIED:20260306T210112Z
UID:8958-1773925200-1773930600@tcaofwa.org
SUMMARY:NAMI Ask the Expert Presents: An Overview of Catatonia
DESCRIPTION:NAMI Ask the Expert Presents: \nAn Overview of Catatonia \nThursday\, March 19\, 2026 | 4:00 – 5:30 p.m. ET \nCatatonia is under-recognized and frequently misdiagnosed\, yet it can have serious consequences when left untreated. \nJoin NAMI for our March Ask the Expert webinar featuring Dr. Scott R. Beach\, associate professor at Harvard Medical School and attending psychiatrist at Massachusetts General Hospital\, for an in-depth and accessible discussion on catatonia and related syndromes. \nYou’ll Learn: \n\nWhat catatonia is and why it is commonly missed or misunderstood\nCommon causes\, risk factors\, and clinical presentations\nEvidence-based treatments\, including benzodiazepines and ECT\nHelpful resources and next steps for individuals showing possible symptoms\n\nWhether you’re seeking answers for yourself\, a loved one\, or your patients\, this session will provide cutting-edge information grounded in the latest research and clinical expertise. \nReserve your spot today and submit your questions for Dr. Beach through the registration form! \nOur Guest Expert \nScott R. Beach\, MD \nPsychiatrist\, Massachusetts General Hospital Acute Psychiatric and Psychiatric Consultation Services \nDr. Scott R. Beach is an attending psychiatrist with the Massachusetts General Hospital Psychiatry Consultation and Acute Psychiatric Services\, and an Associate Professor of Psychiatry at Harvard Medical School. He is the former Program Director for the MGH/McLean Adult Psychiatry Residency. He attended the University of Virginia School of Medicine and completed a residency in Adult Psychiatry at the University of Virginia. He finished a fellowship in Consultation-Liaison Psychiatry at the Massachusetts General Hospital. Dr. Beach has clinical and scholarly areas of expertise in catatonia and related syndromes\, QT prolongation and psychiatric medications\, and the neuropsychiatric effects of COVID-19. \nRegister here: Webinar Registration – Zoom
URL:https://tcaofwa.org/event/nami-ask-the-expert-presents-an-overview-of-catatonia/
LOCATION:Online
CATEGORIES:Advocacy,Behavioral Health,Treatment
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-06-125912.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260310T090000
DTEND;TZID=America/Los_Angeles:20260310T101500
DTSTAMP:20260302T212739Z
CREATED:20260302T212739Z
LAST-MODIFIED:20260302T212739Z
UID:8948-1773133200-1773137700@tcaofwa.org
SUMMARY:Advancing Treatment Provider Training
DESCRIPTION:Brought to you by All Rise: \nFirst session: Tuesday\, March 10\nAll Rise’s Treatment Court Institute will again host its popular virtual training series: advanced adult treatment provider training. This series is designed for treatment professionals working with justice-involved individuals impacted by substance use and co-occurring disorders who are ready to take their knowledge and skills to the next level. \nThe first session will be held on Tuesday\, March 10 at 12:00 p.m. ET; don’t wait\, register today! \nSession 1: Gambling\, Behavioral Addictions\, and Hidden Risk in Justice Populations\nProblem gambling and other behavioral addictions are significantly overrepresented among justice-involved populations\, yet they remain largely unrecognized in most treatment court and supervision settings. When left unidentified\, gambling disorder can quietly undermine treatment engagement\, destabilize recovery\, fuel criminal behavior\, and be misinterpreted by courts as irresponsibility or defiance rather than a treatable condition. \nThis session brings clinical clarity to a frequently overlooked issue. Participants will explore gambling disorder as a diagnosable behavioral addiction\, examine the complex intersections between gambling\, other mental health disorders\, substance use\, impulsivity\, and criminal justice involvement\, and identify why traditional substance use disorder treatment models often fail to detect or address gambling problems. \n\n\n\nLEARN MORE + REGISTER\n\n\n\nAbout the Series\nThis in-depth training series builds advanced skills in treatment planning\, courtroom collaboration\, ethical decision making\, and evidence-based care delivery. There are six virtual training sessions in the series planned for 2026\, each of which will be led by All Rise staff or faculty experts and will offer actionable insights for immediate use in the field. All sessions will be held from 12:00 to 1:15 p.m. ET. \nPresenters:\nSarah Nelson\, Ph.D.\nSarah Nelson is the director of research at the Division on Addiction\, Cambridge Health Alliance\, and an associate professor in the department of psychiatry at Harvard Medical School. Dr. Nelson’s work covers many facets of addiction\, including the relationship between psychiatric comorbidity and impaired driving\, how best to develop community recovery environments for youth with substance use problems\, and the distribution and determinants of gambling problems. She has led the development\, implementation\, and evaluation of the Computerized Assessment and Referral System (CARS) at impaired driving programs and courts across the country. Dr. Nelson’s gambling work has focused on predicting the development of gambling problems\, improving screening and assessment of gambling problems\, and evaluating gambling interventions such as voluntary self exclusion. \nJulie Seitz\, L.A.D.C.\, L.G.S.W.\, M.S.W.\nJulie Seitz is a project director with Impaired Driving Solutions\, a division of All Rise\, providing national training and technical assistance to treatment courts and justice-system partners. With more than 25 years of experience\, her work spans clinical practice\, community-based program development\, and systems transformation. Ms. Seitz is an adjunct social work faculty member at The College of St. Scholastica and an editor and contributor with the American Society of Addiction Medicine (ASAM)\, supporting national guidance related to the ASAM Criteria and evidence-based clinical standards. She is a frequent national and international presenter and is known for helping systems move beyond one-size-fits-all approaches toward individualized\, measurable\, and effective practice. \n  \nUpcoming Sessions: \n\n\n\nSession 2: Contingency Management and Behavioral Reinforcement in Justice Settings\nSession 3: Clinical vs. Forensic Drug Testing\nSession 4: Mental Health\, Trauma\, and Justice Involvement\n\n\n\n\n\n\nSession 5: The Sequential Intercept Model and Justice-Involved Individuals: Advancing Recovery-Oriented Responses Across the Criminal Justice Continuum\nSession 6: Ethics and Confidentiality in Treatment Courts: Navigating Complexities in Clinical and Legal Practice
URL:https://tcaofwa.org/event/advancing-treatment-provider-training/
LOCATION:Online
CATEGORIES:Best Practices,Treatment
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-02-132646.png
END:VEVENT
END:VCALENDAR